Mass spectrometric analysis of glycans in elucidating the pathogenesis of CDG type IIx
- PMID: 12889655
- DOI: 10.1023/a:1024476915278
Mass spectrometric analysis of glycans in elucidating the pathogenesis of CDG type IIx
Abstract
The majority of secreted or membrane-bound proteins are glycosylated. The glycans attached to glycoproteins can affect a range of physicochemical and biological properties of the glycoprotein and appropriate glycosylation is essential for many normal cellular functions, with aberrant glycosylation often leading to disease. This short review briefly outlines the methodology used to release glycans from proteins and analyse them by mass spectrometry. The technology is illustrated by the description of a rapid and sensitive method for profiling glycoproteins of patients with congenital disorders of glycosylation type II. This methodology can rapidly pinpoint the defective step(s) in the processing pathway of N-linked glycans, thereby focusing the biochemical analyses that need to be performed to define the genetic basis of these diseases.
Similar articles
-
Mass spectrometry glycophenotype characterization of ALG2-CDG in Argentinean patients with a new genetic variant in homozygosis.Glycoconj J. 2021 Apr;38(2):191-200. doi: 10.1007/s10719-021-09976-w. Epub 2021 Mar 1. Glycoconj J. 2021. PMID: 33644825
-
A rapid mass spectrometric strategy for the characterization of N- and O-glycan chains in the diagnosis of defects in glycan biosynthesis.Proteomics. 2007 Jun;7(11):1800-13. doi: 10.1002/pmic.200600977. Proteomics. 2007. PMID: 17520685
-
Clinical and biochemical characterization of a patient with congenital disorder of glycosylation (CDG) IIx.J Pediatr. 2005 Dec;147(6):851-3. doi: 10.1016/j.jpeds.2005.07.038. J Pediatr. 2005. PMID: 16356446
-
The impact of mass spectrometry in the diagnosis of congenital disorders of glycosylation.J Inherit Metab Dis. 2011 Aug;34(4):891-9. doi: 10.1007/s10545-011-9306-8. Epub 2011 Mar 8. J Inherit Metab Dis. 2011. PMID: 21384227 Review.
-
Mass spectrometry for congenital disorders of glycosylation, CDG.J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jun 21;838(1):3-8. doi: 10.1016/j.jchromb.2006.02.028. Epub 2006 Mar 6. J Chromatogr B Analyt Technol Biomed Life Sci. 2006. PMID: 16517226 Review.
Cited by
-
Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II.Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3764-9. doi: 10.1073/pnas.0507685103. Epub 2006 Feb 28. Proc Natl Acad Sci U S A. 2006. PMID: 16537452 Free PMC article.
-
Golgi function and dysfunction in the first COG4-deficient CDG type II patient.Hum Mol Genet. 2009 Sep 1;18(17):3244-56. doi: 10.1093/hmg/ddp262. Epub 2009 Jun 3. Hum Mol Genet. 2009. PMID: 19494034 Free PMC article.
-
A novel congenital disorder of glycosylation type without central nervous system involvement caused by mutations in the phosphoglucomutase 1 gene.J Inherit Metab Dis. 2013 May;36(3):535-42. doi: 10.1007/s10545-012-9525-7. Epub 2012 Sep 14. J Inherit Metab Dis. 2013. PMID: 22976764
-
Glycan analysis by reversible reaction to hydrazide beads and mass spectrometry.Anal Chem. 2012 Mar 6;84(5):2232-8. doi: 10.1021/ac202769k. Epub 2012 Feb 10. Anal Chem. 2012. PMID: 22304307 Free PMC article.
-
MAN1B1 deficiency: an unexpected CDG-II.PLoS Genet. 2013;9(12):e1003989. doi: 10.1371/journal.pgen.1003989. Epub 2013 Dec 12. PLoS Genet. 2013. PMID: 24348268 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources